AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26768924 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 126
Study 26768924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propofol and sevoflurane (Group PS)
Number of subjects: 126
Study 26768924 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 126
Study 23917853 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation
Number of subjects: 68
Study 23917853 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation
Number of subjects: 68
Study 22927775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg.kg(‐1)
Number of subjects: 119
Study 22927775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-lidocaine mixture (20 mg lidocaine with 180 mg 1% propofol)
Number of subjects: 119
Study 22927775 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (Control group)
Number of subjects: 119
Study 20692774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation until 6cm of cervical dilation
Number of subjects: 200
Study 20692774 — intervention group
Group type: COMPARATOR
Intervention: Confined to bed in dorsal or lateral recumbence
Number of subjects: 200
Study 18971479 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (acetylcholinesterase inhibitor)
Number of subjects: 28
Study 18971479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 28
Study 16420891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 54
Study 16420891 — intervention group
Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 54
Study 11777514 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg per hour
Number of subjects: 80
Study 11777514 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.0 mg/kg per hour
Number of subjects: 80
Study 11777514 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg per hour
Number of subjects: 80
Study 11777514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10374081 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked quality assessment
Number of subjects: 127
Study 10374081 — intervention group
Group type: COMPARATOR
Intervention: Unmasked quality assessment
Number of subjects: 127
Study 10374081 — intervention group
Group type: COMPARATOR
Intervention: Low-quality trials
Number of subjects: 127
Study 10374081 — intervention group
Group type: COMPARATOR
Intervention: Inadequate allocation concealment
Number of subjects: 127
Study 10374081 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 127
Study 10374081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low quality trials only
Number of subjects: 127
Study 10374081 — intervention group
Group type: COMPARATOR
Intervention: High quality trials only
Number of subjects: 127
Study 10374081 — intervention group
Group type: EXPERIMENTAL
Intervention: All trial scores as quality weights
Number of subjects: 127
Study 7627338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hMG at a daily dose of 150 IU in combination with buserelin
Number of subjects: 14
Study 7627338 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile intravenous hMG at a daily dose of 112.5 IU in combination with buserelin
Number of subjects: 14
Study 2039326 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose cefazolin
Number of subjects: 208
Study 2039326 — intervention group
Group type: COMPARATOR
Intervention: Six-dose cefazolin
Number of subjects: 208
Study 31335805 — intervention group
Group type: EXPERIMENTAL
Intervention: raltegravir and lamivudine
Number of subjects: 75
Study 31335805 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 75
Study 30391919 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 5
Study 30391919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 27187101 — intervention group
Group type: EXPERIMENTAL
Intervention: S+ (379 ± 31 W)
Number of subjects: 12
Study 27187101 — intervention group
Group type: EXPERIMENTAL
Intervention: S- (305 ± 23 W)
Number of subjects: 12
Study 27187101 — intervention group
Group type: EXPERIMENTAL
Intervention: RCP (254 ± 26 W)
Number of subjects: 12
Study 27187101 — intervention group
Group type: EXPERIMENTAL
Intervention: S+
Number of subjects: 12
Study 27187101 — intervention group
Group type: EXPERIMENTAL
Intervention: RCP
Number of subjects: 12
Study 25102960 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 multiple-breath washout
Number of subjects: 60
Study 25102960 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 vital capacity SBW
Number of subjects: 60
Study 25102960 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG-SBW
Number of subjects: 60
Study 22522918 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 27
Study 22522918 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 27
Study 20127230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cladribine
Number of subjects: 0
Study 20127230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18482515 — intervention group
Group type: EXPERIMENTAL
Intervention: High strength GIC (Ketac Molar-3M ESPE)
Number of subjects: 46
Study 18482515 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified GIC (Fuji VIII-GC Corp)
Number of subjects: 46
Study 16137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination program in nursing homes
Number of subjects: 8000
Study 16137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing homes with pneumococcal immunization programs
Number of subjects: 8000
Study 12377315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fractionated preoperative radiotherapy (5 x 5 Gy)
Number of subjects: 98
Study 12377315 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 98
Study 11122794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive chemotherapy
Number of subjects: 0
Study 11122794 — intervention group
Group type: COMPARATOR
Intervention: High-dose chemotherapy
Number of subjects: 0
Study 11122794 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose therapy
Number of subjects: 0
Study 11122794 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized studies
Number of subjects: 0
Study 7572019 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline 35 mg.ml‐1 (Haemaccel)
Number of subjects: 40
Study 7572019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex) 60 mg.ml‐1
Number of subjects: 40
Study 7572019 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (RAc)
Number of subjects: 40
Study 7572019 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid groups (polygeline, dextran, albumin)
Number of subjects: 40
Study 7572019 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 40 mg.ml‐1 in saline
Number of subjects: 40
Study 2157734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% (w/v) NaHCO3
Number of subjects: 25
Study 2157734 — intervention group
Group type: COMPARATOR
Intervention: 0.9% (w/v) NaCl
Number of subjects: 25
Study 7000227 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole (1-g suppository with premedication and 200 mg t.d.s. orally for 7 days)
Number of subjects: 170
Study 7000227 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 170
Study 7000227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 170
Study 7000227 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole
Number of subjects: 170
Study 7000227 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture of the appendix
Number of subjects: 170
Study 31138301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (exact dosage and duration not specified)
Number of subjects: 0
Study 28087506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg at weeks 0, 4 and every 8 weeks
Number of subjects: 274
Study 28087506 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 50 mg at weeks 0, 4 and every 8 weeks
Number of subjects: 274
Study 28087506 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg at weeks 0, 4 and every 8 weeks
Number of subjects: 274
Study 28087506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 26177541 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tPCSPD = 500
Number of subjects: 0
Study 26177541 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tPCSPD = 250
Number of subjects: 0
Study 26177541 — intervention group
Group type: COMPARATOR
Intervention: sham a‐tPCS
Number of subjects: 0
Study 24238770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training plus breathing-retraining and oxygen (n=35)
Number of subjects: 192
Study 24238770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training plus heliox (n=33)
Number of subjects: 192
Study 24238770 — intervention group
Group type: COMPARATOR
Intervention: Exercise-training plus oxygen (n=35)
Number of subjects: 192
Study 24238770 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-retraining plus oxygen
Number of subjects: 192
Study 24238770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training plus breathing-retraining and oxygen
Number of subjects: 192
Study 24238770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training plus heliox
Number of subjects: 192
Study 21161742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of an IL‐1 inhibitor
Number of subjects: 0
Study 21161742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19067085 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored navigator program including educational material, phone or in-person contact by language-concordant navigators, patient education, procedure scheduling, translation of bowel preparation, and assistance with transportation and insurance coverage.
Number of subjects: 1223
Study 19067085 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 1223
Study 19067085 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored navigator program.
Number of subjects: 1223
Study 15996033 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose H(2)RAs
Number of subjects: 0
Study 15996033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose proton pump inhibitors
Number of subjects: 0
Study 15996033 — intervention group
Group type: COMPARATOR
Intervention: Standard dose other proton pump inhibitors
Number of subjects: 0
Study 15996033 — intervention group
Group type: COMPARATOR
Intervention: Standard dose omeprazole
Number of subjects: 0
Study 12590652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 12590652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10021302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 32
Study 10021302 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated)
Number of subjects: 32
Study 8762358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse visit with health education (group A)
Number of subjects: 799
Study 8762358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse visit without health education (group B)
Number of subjects: 799
Study 8762358 — intervention group
Group type: EXPERIMENTAL
Intervention: GP letter (group C)
Number of subjects: 799
Study 8762358 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A and group C
Number of subjects: 799
Study 8762358 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group B and group C
Number of subjects: 799
Study 8762358 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A and group B
Number of subjects: 799
Study 1907907 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg/day
Number of subjects: 43
Study 1907907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 1907907 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 43
Study 7066137 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg‐1
Number of subjects: 0
Study 7066137 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.1-0.4 mg kg‐1)
Number of subjects: 0
Study 7066137 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional injections of etomidate
Number of subjects: 0
Study 7066137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of etomidate
Number of subjects: 0
Study 31838148 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate training group (MG)
Number of subjects: 48
Study 31838148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training group (IG)
Number of subjects: 48
Study 30597719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic SCS device (primo-implant)
Number of subjects: 402
Study 30597719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic SCS device (replacement implant)
Number of subjects: 402
Study 30597719 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (both groups)
Number of subjects: 402
Study 28224443 — intervention group
Group type: COMPARATOR
Intervention: SAP (strengthening, agility, and secondary prevention)
Number of subjects: 40
Study 28224443 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP+PERT (SAP protocol with the addition of perturbation training)
Number of subjects: 40
Study 26125923 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 68
Study 26125923 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 68
Study 22775239 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-102 6 mg
Number of subjects: 24
Study 22775239 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-102 2 mg
Number of subjects: 24
Study 22775239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 24
Study 22775239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 24
Study 22775239 — intervention group
Group type: COMPARATOR
Intervention: ABT-102 0.5 mg
Number of subjects: 24
Study 21156319 — intervention group
Group type: EXPERIMENTAL
Intervention: oxLDL immune complexes (oxLDL-IC)
Number of subjects: 476
Study 18462100 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraceptive use
Number of subjects: 1686
Study 18462100 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of seroprevalent and seronegative women)
Number of subjects: 1686
Study 18462100 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma virus set point
Number of subjects: 1686
Study 16778652 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA implant
Number of subjects: 60
Study 16778652 — intervention group
Group type: COMPARATOR
Intervention: Collagen implant
Number of subjects: 60
Study 15006580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant chemotherapy (9 cycles of 5 days every 4 weeks; daily administration of 200 mg/m² folinic acid, 5-fluorouracil starting at 375 mg/m² increasing to 500 mg/m², and CDDP 15 mg/m²)
Number of subjects: 205
Study 15006580 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 205
Study 11732150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A fortified biscuits with de-worming treatment
Number of subjects: 579
Study 11732150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A fortified biscuits without de-worming treatment
Number of subjects: 579
Study 11732150 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihelminthic treatment
Number of subjects: 579
Study 11732150 — intervention group
Group type: COMPARATOR
Intervention: Unfortified biscuits
Number of subjects: 579
Study 9219700 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.5 to 0.8 mg/kg/day) and aspirin (100 mg/day)
Number of subjects: 202
Study 9219700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 9219700 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and aspirin
Number of subjects: 202
Study 8195582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 115 mg/day
Number of subjects: 43
Study 8195582 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 3.2 mg/day
Number of subjects: 43
Study 3591728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-histidine complexes (1:2 ratio)
Number of subjects: 10
Study 3591728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-histidine complexes (1:12 ratio)
Number of subjects: 10
Study 3591728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-histidine (15 mg)
Number of subjects: 10
Study 3591728 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate
Number of subjects: 10
Study 3591728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc preparations (both zinc-histidine and zinc sulfate)
Number of subjects: 10
Study 29900565 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330811
Number of subjects: 40
Study 29900565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27665195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (19 fractions of 3.4 Gy)
Number of subjects: 820
Study 27665195 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (39 fractions of 2 Gy)
Number of subjects: 820
Study 27665195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated treatment
Number of subjects: 820
Study 27665195 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated treatment vs Conventional treatment
Number of subjects: 820
Study 24964505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K antagonists (VKAs)
Number of subjects: 93
Study 24964505 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 93
Study 24964505 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal cognitive function (MMSE = 24-27)
Number of subjects: 93
Study 24964505 — intervention group
Group type: EXPERIMENTAL
Intervention: Disturbances of cognitive function (MMSE < 24)
Number of subjects: 93
Study 24964505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function disturbances
Number of subjects: 93
Study 22079063 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lag screw and arch bar
Number of subjects: 20
Study 22079063 — intervention group
Group type: COMPARATOR
Intervention: Two lag screws
Number of subjects: 20
Study 20026501 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of abduction treatment
Number of subjects: 128
Study 20026501 — intervention group
Group type: COMPARATOR
Intervention: Active-sonographic-surveillance
Number of subjects: 128
Study 20026501 — intervention group
Group type: COMPARATOR
Intervention: Both groups (treatment and surveillance)
Number of subjects: 128
Study 18164001 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive pill (ethinylestradiol plus norethisterone)
Number of subjects: 100
Study 18164001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16816278 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 1531
Study 16816278 — intervention group
Group type: COMPARATOR
Intervention: Enhanced specialty referral
Number of subjects: 1531
Study 14674822 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-monitors
Number of subjects: 0
Study 14674822 — intervention group
Group type: COMPARATOR
Intervention: Low self-monitors
Number of subjects: 0
Study 11119090 — intervention group
Group type: EXPERIMENTAL
Intervention: Water containing 2% ethanol for irrigation during TURP
Number of subjects: 100
Study 9362598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program for high disease activity patients
Number of subjects: 0
Study 9362598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program for low disease activity patients
Number of subjects: 0
Study 9362598 — intervention group
Group type: COMPARATOR
Intervention: Control group for high disease activity patients
Number of subjects: 0
Study 9362598 — intervention group
Group type: COMPARATOR
Intervention: Control group for low disease activity patients
Number of subjects: 0
Study 1348168 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/70 kg dezocine
Number of subjects: 10
Study 1348168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/70 kg dezocine
Number of subjects: 10
Study 1348168 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/70 kg dezocine
Number of subjects: 10
Study 1348168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg dezocine
Number of subjects: 10
Study 3760278 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared coagulator
Number of subjects: 0
Study 3760278 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 0
Study 28766913 — intervention group
Group type: EXPERIMENTAL
Intervention: PC support with texting (Lactation Advice thru Texting Can Help intervention)
Number of subjects: 58
Study 28766913 — intervention group
Group type: COMPARATOR
Intervention: PC support without texting (control)
Number of subjects: 58
Study 27126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg/day for 5 days, started the next day after finishing medroxyprogesterone acetate course (early induction)
Number of subjects: 90
Study 27126971 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day for 5 days, started on day 2 of withdrawal bleeding (late induction)
Number of subjects: 90
Study 24325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14
Study 24325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14
Study 24325778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Simvastatin and Bezafibrate
Number of subjects: 14
Study 24325778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23038702 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1 g/d, n = 46)
Number of subjects: 96